Last reviewed · How we verify

NCT04207970

Evaluating Adapted Structured Clinical Management for People With a Diagnosis of Personality Disorder

Completed Last updated 28 January 2021
What this trial tests

trial testing Adapted Structured Clinical Management in Personality Disorders in 27 participants. Completed in 31 August 2020.

Timeline
19 December 2019
Primary endpoint
1 June 2020
31 August 2020

Quick facts

Lead sponsorCamden and Islington NHS Trust
StatusCompleted
Study typeOBSERVATIONAL
Enrollment27
Start date19 December 2019
Primary completion1 June 2020
Estimated completion31 August 2020
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Camden and Islington NHS Trust

Who can join

18 and older, any sex, with Personality Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Camden and Islington NHS Foundation Trust in London has a Personality Disorder Service (PDS) which offers a number of evidence-based interventions to people with a diagnosis of Personality Disorder. One team in the PDS, the Community Team, offers an adapted form of Structured Clinical Management (SCM; Bateman and Kravitz, 2013). As these adaptations are novel, this study aims to formally explore the effectiveness of this intervention, through a sample of clients under the team, with outcomes (proxy measures of distress such as inpatient admissions) pre- and post- intervention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Personality Disorders

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04207970.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing